CSL Ltd Annual Report 2019

Product registrations and indications 2018/19* Therapy area Product Type Country/region Immunology and neurology products Focus on improved patient convenience, plasma yield improvements, expanded labels, new formulation science and recombinant technology. HIZENTRA ® Immune Globulin Subcutaneous (Human) 20% Liquid NR Indonesia, Singapore HIZENTRA ® Immune Globulin Subcutaneous (Human) 20% Liquid NI Australia, Canada, Chile, Japan, Peru, Puerto Rico, Switzerland PRIVIGEN ® Immune Globulin Intravenous (Human) 10% Liquid NR Indonesia, Japan, Singapore, Uruguay PRIVIGEN ® Immune Globulin Intravenous (Human) 10% Liquid NI Europe, Trinidad and Tobago, United Arab Emirates BERINERT ® C1-Esterase Inhibitor Intravenous, Human NR Iceland BERINERT ® P C1-Esterase Inhibitor Intravenous, Human NI Iran RHOPHYLAC ® Rho(D) Immune Globulin Intravenous (Human) NR Chile, Panama TETAGAM ® P Tetanus Immunoglobulin (Human) NR Malta ALBUREX ® 5/20, ALBURX ® 20/25, Human Albumin NR Dominican Republic, Lebanon, Malta, Paraguay, Sri Lanka, Thailand XADAGO ™ for Parkinson’s Disease (Seqirus) NR † Australia TEGLUTIK ® for Amyotrophic Lateral Sclerosis (ALS) a form of Motor Neurone Disease (Seqirus) NR ‡ Australia Haematology and thrombosis products Maximise the value and performance of our existing coagulation therapies and develop new protein and gene-based therapies. IDELVION ® Coagulation Factor IX (Recombinant) Albumin Fusion Protein NR Brazil, Thailand AFSTYLA ® Coagulation Factor VIII (Recombinant) NR Hong Kong, Taiwan BERIATE ® Coagulation Factor VIII (Human) NR Indonesia VONCENTO ® Coagulation Factor VIII (Human)/vonWillebrand Factor (Human) NR Brazil MONONINE ® Coagulation Factor IX (Human) Monoclonal Antibody Purified NR Brazil, Honduras RiaSTAP ® Fibrinogen Concentrate (Human) NR New Zealand Respiratory products Develop new treatments for respiratory diseases using our existing plasma-derived immunoglobulins and proteins and recombinant monoclonal antibody technology. ZEMAIRA ® Alpha1 Proteinase Inhibitor (Human) NR Colombia Vaccines Develop products for the prevention of infectious diseases. AFLURIA ® Trivalent ™ , seasonal egg-based split trivalent inactivated influenza vaccine NI US AFLURIA ® Quadrivalent ™ , seasonal egg-based split inactivated quadrivalent influenza vaccine NI US AFLURIA ® QUAD, seasonal egg-based split inactivated quadrivalent influenza vaccine NI Australia AFLURIA ® QUAD Junior, seasonal egg-based split inactivated quadrivalent influenza vaccine NR Australia AFLURIA ® QUAD Junior, seasonal egg-based split inactivated quadrivalent influenza vaccine PQ World Health Organization (WHO) FLUCELVAX ® TETRA, cell culture-based inactivated influenza vaccine NR Europe * First-time registrations or indications for CSL products in the listed countries/regions over the reporting period. NR = New Registration. NI = New Indication. PQ = Prequalification (via WHO). † XADAGO™ is a trademark of Zambon S.p.A. Under Licence from Newron Pharmaceuticals S.p.A. XADAGO is distributed by Seqirus (Australia) Pty Ltd under licence from Zambon S.p.A. ‡ TEGLUTIK® is a registered trademark of Italfarmaco S.A., Spain. TEGLUTIK® is distributed by Seqirus (Australia) Pty Ltd under license from Italfarmaco S.A., Spain. CSL Limited Annual Report 2019 17